RAPHAEL MORRIS: Open Payments
NPI 1801811104 · DEL MAR, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$721 in 24 payments from 8 companies in 2025. Trend: 2023 $722 · 2024 $285 · 2025 $721
Food & beverage: $619Education: $101
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 5 | $206 |
| Vanda Pharmaceuticals Inc. | 6 | $144 |
| Teva Pharmaceuticals USA, Inc. | 2 | $136 |
| Neuronetics, Inc. | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: LYBALVI, FANAPT, NEUROSTAR TMS THERAPY SYSTEM, TRINTELLIX, ARISTADA, AUSTEDO XR, CAPLYTA, INGREZZA.
Industry payments across CA — which companies pay providers there.
